{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:15:48Z","timestamp":1755796548305,"version":"3.44.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,17]]},"DOI":"10.7759\/cureus.90352","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T06:49:03Z","timestamp":1755499743000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the Effectiveness and Safety of Vedolizumab in Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Abdulraouf","family":"Flemban","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamzah  A","family":"Bakhor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghad","family":"Almuzaini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taif","family":"Alshahrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghid  A","family":"Alahmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raneem","family":"Alshurbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaldah","family":"Althobiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hams","family":"Alwadai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sufyan","family":"Maghrabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najwa","family":"Alkhairy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moath","family":"Shawosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taghreed","family":"Zamzami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro R","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017, 389:1756-70.","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins L","year":"2012","unstructured":"Jostins L, Ripke S, Weersma RK, et al.. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012, 491:119-24. 10.1038\/nature11582","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-303661","article-title":"Geographical variability and environmental risk factors in inflammatory bowel disease","volume":"62","author":"Ng SC","year":"2013","unstructured":"Ng SC, Bernstein CN, Vatn MH, et al.. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut. 2013, 62:630-49. 10.1136\/gutjnl-2012-303661","journal-title":"Gut"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.34","article-title":"Epidemiology and risk factors for IBD","volume":"12","author":"Ananthakrishnan AN","year":"2015","unstructured":"Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015, 12:205-17. 10.1038\/nrgastro.2015.34","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort","volume":"106","author":"Vavricka SR","year":"2011","unstructured":"Vavricka SR, Brun L, Ballabeni P, et al.. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011, 106:110-9. 10.1038\/ajg.2010.343","journal-title":"Am J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.02.030","article-title":"High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test","volume":"10","author":"Crotta S","year":"2012","unstructured":"Crotta S, Segnan N, Paganin S, Dagnes B, Rosset R, Senore C. High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin Gastroenterol Hepatol. 2012, 10:633-8. 10.1016\/j.cgh.2012.02.030","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management","volume":"11","author":"Harbord M","year":"2017","unstructured":"Harbord M, Eliakim R, Bettenworth D, et al.. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017, 11:769-84. 10.1093\/ecco-jcc\/jjx009","journal-title":"J Crohns Colitis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2020.10.001","article-title":"Ileitis as the exclusive manifestation of COVID-19. The first reported case","volume":"44","author":"Brunet E","year":"2021","unstructured":"Brunet E, Casabella A, Calzado S, Villoria A. Ileitis as the exclusive manifestation of COVID-19. The first reported case. Gastroenterol Hepatol. 2021, 44:561-3. 10.1016\/j.gastrohep.2020.10.001","journal-title":"Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.03.005","article-title":"Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression analysis","volume":"18","author":"Pastori D","year":"2019","unstructured":"Pastori D, Bucci T, Triggiani M, et al.. Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression analysis. Autoimmun Rev. 2019, 18:519-25. 10.1016\/j.autrev.2019.03.005","journal-title":"Autoimmun Rev"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative colitis","volume":"380","author":"Ord\u00e1s I","year":"2012","unstructured":"Ord\u00e1s I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012, 380:1606-19.","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0546-0","article-title":"A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab","volume":"56","author":"Rosario M","year":"2017","unstructured":"Rosario M, Dirks NL, Milch C, et al.. A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab. Clin Pharmacokinet. 2017, 56:1287-301. 10.1007\/s40262-017-0546-0","journal-title":"Clin Pharmacokinet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw070","article-title":"Similar depletion of protective Faecalibacterium prausnitzii in psoriasis and inflammatory bowel disease, but not in hidradenitis suppurativa","volume":"10","author":"Eppinga H","year":"2016","unstructured":"Eppinga H, Sperna Weiland CJ, Thio HB, van der Woude CJ, Nijsten TE, Peppelenbosch MP, Konstantinov SR. Similar depletion of protective Faecalibacterium prausnitzii in psoriasis and inflammatory bowel disease, but not in hidradenitis suppurativa. J Crohns Colitis. 2016, 10:1067-75. 10.1093\/ecco-jcc\/jjw070","journal-title":"J Crohns Colitis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler D","year":"2009","unstructured":"Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009, 330:864-75. 10.1124\/jpet.109.153973","journal-title":"J Pharmacol Exp Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4082\/kjfm.23.0034","article-title":"Robans 2: a revised risk of bias assessment tool for nonrandomized studies of interventions","volume":"44","author":"Seo HJ","year":"2023","unstructured":"Seo HJ, Kim SY, Lee YJ, Park JE. Robans 2: a revised risk of bias assessment tool for nonrandomized studies of interventions. Korean J Fam Med. 2023, 44:249-60. 10.4082\/kjfm.23.0034","journal-title":"Korean J Fam Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins JP","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002, 21:1539-58. 10.1002\/sim.1186","journal-title":"Stat Med"},{"key":"ref17","article-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins JPT","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons, Chichester, UK; 2019."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1159\/000488401","article-title":"Patent foramen ovale and cryptogenic stroke or transient ischemic attack: to close or not to close? A systematic review and meta-analysis","volume":"45","author":"Lattanzi S","year":"2018","unstructured":"Lattanzi S, Brigo F, Cagnetti C, Di Napoli M, Silvestrini M. Patent foramen ovale and cryptogenic stroke or transient ischemic attack: to close or not to close? A systematic review and meta-analysis. Cerebrovasc Dis. 2018, 45:193-203. 10.1159\/000488401","journal-title":"Cerebrovasc Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00708-6","article-title":"Adjunctive cannabidiol in patients with Dravet syndrome: a systematic review and meta-analysis of efficacy and safety","volume":"34","author":"Lattanzi S","year":"2020","unstructured":"Lattanzi S, Brigo F, Trinka E, Zaccara G, Striano P, Del Giovane C, Silvestrini M. Adjunctive cannabidiol in patients with Dravet syndrome: a systematic review and meta-analysis of efficacy and safety. CNS Drugs. 2020, 34:229-41. 10.1007\/s40263-020-00708-6","journal-title":"CNS Drugs"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16546","article-title":"Cannabidiol efficacy and clobazam status: a systematic review and meta-analysis","volume":"61","author":"Lattanzi S","year":"2020","unstructured":"Lattanzi S, Trinka E, Striano P, et al.. Cannabidiol efficacy and clobazam status: a systematic review and meta-analysis. Epilepsia. 2020, 61:1090-8. 10.1111\/epi.16546","journal-title":"Epilepsia"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00759-9","article-title":"Adjunctive cenobamate for focal-onset seizures in adults: a systematic review and meta-analysis","volume":"34","author":"Lattanzi S","year":"2020","unstructured":"Lattanzi S, Trinka E, Zaccara G, Striano P, Del Giovane C, Silvestrini M, Brigo F. Adjunctive cenobamate for focal-onset seizures in adults: a systematic review and meta-analysis. CNS Drugs. 2020, 34:1105-20. 10.1007\/s40263-020-00759-9","journal-title":"CNS Drugs"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.48338","article-title":"Safety and efficacy of biologic therapies (ustekinumab and vedolizumab) in the treatment of inflammatory bowel disease (IBD): a systematic review","volume":"15","author":"Ashraf H","year":"2023","unstructured":"Ashraf H, Bodapati A, Hanif A, Okafor DK, Katyal G, Kaur G, Khan S. Safety and efficacy of biologic therapies (ustekinumab and vedolizumab) in the treatment of inflammatory bowel disease (IBD): a systematic review. Cureus. 2023, 15:e48338. 10.7759\/cureus.48338","journal-title":"Cureus"},{"key":"ref23","article-title":"Ulcerative colitis","author":"Lynch WD","year":"2025","unstructured":"Lynch WD, Hsu R. Ulcerative colitis. StatPearls. StatPearls Publishing, Treasure Island, FL; 2025."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/397377-evaluating-the-effectiveness-and-safety-of-vedolizumab-in-moderate-to-severe-ulcerative-colitis-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T06:49:04Z","timestamp":1755499744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/397377-evaluating-the-effectiveness-and-safety-of-vedolizumab-in-moderate-to-severe-ulcerative-colitis-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,17]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.90352","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,8,17]]}}}